Menus Subscribe Search

Follow us


Mosquito sucking blood

(PHOTO: SHUTTERSTOCK)

Update: Many Malaria Meds Still Fake, and Now the Real Ones Are Iffy Too

• November 15, 2012 • 9:21 AM

(PHOTO: SHUTTERSTOCK)

Over the summer we we reported the curious story behind a National Institutes of Health study, which had found a third of malaria medications taken around the world are fake. Most commentary on the research intimated that unscrupulous, large, likely Chinese pharmaceutical companies were to blame. It turned out the dummy pills were actually produced by small criminal syndicates, shoestring counterfeit operations run in garages and back rooms, pushing fake meds in convincing packaging to customers in their own communities. Fortunately, none of this would matter soon, we thought—because a promising vaccine against malaria was on the way. In a generation malaria would be, if not gone, certainly on its heels.

This week, the final trial on that promising vaccine will appear in the New England Journal of Medicine—and the surprising results are not encouraging. After an earlier trial showed that more than sixty percent of older children vaccinated would become resistant to the disease, follow-up trials on infants have fallen disappointingly short. In the latest trial, only thirty percent of children showed resistance, and that appears likely to wane dramatically after the first year.

It’s a huge setback for the program and will delay deployment by years—the hope had been 2015. Instead, the weapons against the disease will continue to be what they have been for decades: affordable treatments, reliable medicines, and public information. Some commentary, notably from voices in malarial regions, questioned this week whether the encouraging results from earlier tests had led to false expectations. That the vaccine is a high-profile project backed heavily by the Gates Foundation and numerous celebrity voices doesn’t help. Indian daily The Hindu took care to note how high previous success had set the bar. Doubts, the paper points out, were in the fine print and the footnotes—incautiously, it now seems:

The vaccine has been developed primarily for infants and children in sub-Saharan Africa. The reasons are obvious: of the 216 million cases of malaria and 6,55,000 malaria-related deaths in 2010, a majority of deaths took place in African countries.

Even as many newspapers went overboard last year based on results from the older age group, the 2011 Editorial accompanying the paper in The New England Journal of Medicine explicitly stated: “there does not seem to be a clear scientific reason why this trial has been reported with less than half the efficacy results available.”

The 2011 paper concluded with a rider that the “vaccine has the potential to have an important effect on the burden of malaria in young African children.” The rider was: the “vaccine efficacy among younger infants and the duration of protection will be critical to determining how this vaccine could be used effectively to control malaria.”

In that sense, the latest results do dampen the high spirits seen last year. The last word is yet to be pronounced. One has to wait till 2014 when the complete data is analysed and the outcome is known. Only then can it be said with any certainty if the vaccine will indeed be included for use in the African countries as per WHO recommendations. WHO had taken the unusual decision last year when it had “recommended” its use in the African countries as early as 2015.

Marc Herman

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts


September 30 • 10:09 AM

Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.


September 30 • 8:00 AM

The Psychology of Penmanship

Graphology: It’s all (probably) bunk.



September 30 • 6:00 AM

The Medium Is the Message, 50 Years Later

Five decades on, what can Marshall McLuhan’s Understanding Media tell us about today?


September 30 • 4:00 AM

Grad School’s Mental Health Problem

Navigating the emotional stress of doctoral programs in a down market.


September 29 • 1:21 PM

Conference Call: Free Will Conference


September 29 • 12:00 PM

How Copyright Law Protects Art From Criticism

A case for allowing the copyright on Gone With the Wind to expire.


September 29 • 10:00 AM

Should We Be Told Who Funds Political Attack Ads?

On the value of campaign finance disclosure.


September 29 • 8:00 AM

Searching for a Man Named Penis

A quest to track down a real Penis proves difficult.


September 29 • 6:00 AM

Why Do So Many People Watch HGTV?

The same reason so many people watch NCIS or Law and Order: It’s all a procedural.


September 29 • 4:00 AM

The Link Between Depression and Terrorism

A new study from the United Kingdom finds a connection between depression and radicalization.


September 26 • 4:00 PM

Fast Track to a Spill?

Oil pipeline projects across America are speeding forward without environmental review.


September 26 • 2:00 PM

Why Liberals Love the Disease Theory of Addiction, by a Liberal Who Hates It

The disease model is convenient to liberals because it spares them having to say negative things about poor communities. But this conception of addiction harms the very people we wish to help.


September 26 • 1:21 PM

Race, Trust, and Split-Second Judgments


September 26 • 9:47 AM

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what’s new and different more attractive.


September 26 • 8:00 AM

A Letter Becomes a Book Becomes a Play

Sarah Ruhl’s Dear Elizabeth: A Play in Letters From Elizabeth Bishop to Robert Lowell and Back Again takes 900 pages of correspondence between the two poets and turns them into an on-stage performance.


September 26 • 7:00 AM

Sonic Hedgehog, DICER, and the Problem With Naming Genes

Wait, why is there a Pokemon gene?


September 26 • 6:00 AM

Sounds Like the Blues

At a music-licensing firm, any situation can become nostalgic, romantic, or adventurous, given the right background sounds.


September 26 • 5:00 AM

The Dark Side of Empathy

New research finds the much-lauded feeling of identification with another person’s emotions can lead to unwarranted aggressive behavior.



September 25 • 4:00 PM

Forging a New Path: Working to Build the Perfect Wildlife Corridor

When it comes to designing wildlife corridors, our most brilliant analytical minds are still no match for Mother Nature. But we’re getting there.


September 25 • 2:00 PM

Fashion as a Inescapable Institution

Like it or not, fashion is an institution because we can no longer feasibly make our own clothes.


September 25 • 12:00 PM

The Fake Birth Mothers Who Bilk Couples Out of Their Cash by Promising Future Babies

Another group that’s especially vulnerable to scams and fraud is that made up of those who are desperate to adopt a child.


September 25 • 10:03 AM

The Way We QuickType


Follow us


Trust Is Waning, and Inequality May Be to Blame

Trust in others and confidence in institutions is declining, while economic inequality creeps up, a new study shows.

Dopamine Might Be Behind Impulsive Behavior

A monkey study suggests the brain chemical makes what's new and different more attractive.

School Counselors Do More Than You’d Think

Adding just one counselor to a school has an enormous impact on discipline and test scores, according to a new study.

How a Second Language Trains Your Brain for Math

Second languages strengthen the brain's executive control circuits, with benefits beyond words.

Would You Rather Go Blind or Lose Your Mind?

Americans consistently fear blindness, but how they compare it to other ailments varies across racial lines.

The Big One

One company, Amazon, controls 67 percent of the e-book market in the United States—down from 90 percent five years ago. September/October 2014 new-big-one-5

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.